# (19) World Intellectual Property Organization

(43) International Publication Date 10 March 2005 (10.03.2005)

International Bureau





PCT

## (10) International Publication Number WO 2005/022164 A2

(51) International Patent Classification7:

English

G01N 33/68

(21) International Application Number:

PCT/EP2004/009199

(22) International Filing Date: 17 August 2004 (17.08.2004)

(25) Filing Language:

(26) Publication Language: English

(30) Priority Data:

03019799.0 30 August 2003 (30.08.2003)

- (71) Applicant (for all designated States except US): BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GOLZ, Stefan [DE/DE]; Bückmannsmühle 46, 45326 Essen (DE). BRÜGGEMEIER, Ulf [DE/DE]; Leysiefen 20, 42799 Leichlingen (DE). GEERTS, Andreas [DE/DE]; Schuckertstr. 29, 42113 Wuppertal (DE). POLEJ, Stefanie [DE/DE]; Feldstr. 10, 78315 Rodolfzell (DE).
- (74) Common Representative: BAYER HEALTHCARE AG; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

### Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH KALLIKREIN 8 (KLK8)

(57) Abstract: The invention provides a human KLK8 which is associated with the cardiovascular diseases, dermatological diseases, neurological diseases, metabolic dieases, cancer disorders, urological diseases, gastroenterological diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, neurological diseases, metabolic dieases, cancer disorders, urological diseases, gastroenterological diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK8 as well as pharmaceutical compositions comprising such compounds.



## (19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 10 March 2005 (10.03.2005)

PCT

## (10) International Publication Number WO 2005/022164 A3

(51) International Patent Classification7: G01N 33/68

(21) International Application Number:

PCT/EP2004/009199

(22) International Filing Date: 17 August 2004 (17.08.2004)

(25) Filing Language:

**English** 

(26) Publication Language:

English

(30) Priority Data: 03019799.0

30 August 2003 (30.08,2003)

- (71) Applicant (for all designated States except US): BAYER **HEALTHCARE AG** [DE/DE]; 51368 Leverkusen (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GOLZ, Stefan [DE/DE]; Bückmannsmühle 46, 45326 Essen (DE). BRÜGGEMEIER, Ulf [DE/DE]; Leysiefen 20, 42799 Leichlingen (DE). GEERTS, Andreas [DE/DE]; Schuckertstr. 29, 42113 Wuppertal (DE). POLEJ, Stefanie [DE/DE]; Feldstr. 10, 78315 Rodolfzell (DE).
- (74) Common Representative: BAYER HEALTHCARE AG; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN. CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH. GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH KALLIKREIN 8 (KLK8)

(57) Abstract: The invention provides a human KLK8 which is associated with the cardiovascular diseases, dermatological diseases, neurological diseases, metabolic dieases, cancer disorders, urological diseases, gastroenterological diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, neurological diseases, metabolic dieases, cancer disorders, urological diseases, gastroenterological diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK8 as well as pharmaceutical compositions comprising such compounds.

